- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
The Medicines Co. v. Mylan, Inc.
The Federal Circuit’s decision on the issue of infringement precludes a trial on remand as to the doctrine of equivalents.
July 14, 2017
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: The Medicines Co. v. Mylan Inc., Civ. No. 11-cv-1285, 2017 U.S. Dist. LEXIS 99898 (N.D. Ill. June 28, 2017) (St. Eve, J.)
Drug Product and U.S. Patent: Angiomax® (bivalirudin); U.S. Patents Nos. 7,582,727 (“the ’727 patent”) and 7,598,343 (“the ’343 patent”)
Nature of the Case and Issue(s) Presented: The issue was whether an infringement trial relating to the doctrine of equivalents should occur after the Federal Circuit affirmed a finding of non-infringement as to one asserted patent and reversed the finding of infringement as to the other asserted patent. Plaintiff argued that the Federal Circuit provided a new claim construction for one limitation and did not expressly rule on whether infringement under the doctrine of equivalents would be available under this new construction. Mylan argued that the Federal Circuit did not remand the case for such determination, but rather decided all issues of infringement in favor of Mylan.
The district court found that the mandate precluded a new infringement trial concerning the issue of equivalents.
Why Mylan Prevailed: The district court held that the mandate applied because the Federal Circuit either affirmed or decided, based on the record, all issues related to infringement. The court noted that the Federal Circuit did not remand the case, but rather affirmed-in-part and reversed-in-part the original ruling of the district court as to infringement. Moreover, the Federal Circuit affirmed that a limitation in both patents was not present in the accused products, such that the issue of infringement was decided by the Federal Circuit and the mandate rule precluded the district court from conducting a new trial on the issue.
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.